EPRX
Eupraxia
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
EPRX Profile
Eupraxia Pharmaceuticals Inc.
A clinical-stage biotechnology company focused on developing innovative drug delivery technologies.
Pharmaceutical
Invalid Date
04/05/2024
NASDAQ Stock Exchange
33
12-31
Common stock
201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4
--
Eupraxia Pharmaceuticals Inc., was incorporated in British Columbia in May 2011. Eupraxia is a clinical-stage biotechnology company focused on developing local delivery, extended-release alternatives to existing drugs to create new products for the "first time" in molecular or drug categories, or "best-in-class" products for indications where efficacy has been established. Leveraging its proprietary and innovative DiffusihereTM delivery technology, Eupraxia's goal is to deliver the right dose of the drug in the right place and at the right time for indications with high unmet medical need. Each of Uprasha's product candidates is designed to improve patient benefit by delivering longer-lasting activity than currently available treatments, combined with improved pharmacokinetics (" PK ") and related safety, and combined with precisely targeted topical delivery.